...In an unexpected friendly tilt, the acquisitive Frankfurt-based Qiagen has offered $341m ($3.55 a share) in cash for Cellestis, a global purveyor of Quantiferon tuberculosis testing kits. The offer -- which might be bolstered by a special franked dividend -- is a 24 per cent premium on Friday's closing price.
....Alas, Criterion had Cellestis as an avoid at $2.75 on February 15, citing the generous multiples on which the stock was trading. The stock is now a hold.
http://www.theaustralian.com.au/business/opinion/cellestis-deal-a-boost-for-busy-sector/story-e6frg9lo-1226033277146
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.65M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 143165 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 126563 | 3 |
View Market Depth
| Last trade - 10.02am 07/08/2025 (20 minute delay) ? |
| CST (ASX) Chart |
Day chart unavailable